menu
    • menu
    [{"orgOrder":0,"company":"Actio Biosciences","sponsor":"Saniona","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ABS-0871","moa":"TRPV4","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Actio Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Actio Biosciences \/ Saniona","highestDevelopmentStatusID":"6","companyTruncated":"Actio Biosciences \/ Saniona"},{"orgOrder":0,"company":"Actio Biosciences","sponsor":"Canaan Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Actio Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actio Biosciences \/ Canaan Partners","highestDevelopmentStatusID":"4","companyTruncated":"Actio Biosciences \/ Canaan Partners"}]

    Find Clinical Drug Pipeline Developments & Deals by Actio Biosciences

    Menu

    Actio Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Actio Biosciences

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Actio Biosciences

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABS-0871

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Saniona

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Actio Biosciences Doses First Participant in ABS-0871 Phase 1 Trial

                            Details : ABS-0871 is a TRPV4 antagonist. small molecule drug candidate, which is currently being evaluated for the treatment of charcot marie tooth disease 2C.

                            Product Name : ABS-0871

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 03, 2025

                            Lead Product(s) : ABS-0871

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Saniona

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Actio Biosciences

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Actio Biosciences

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Canaan Partners

                            Deal Size : $55.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Actio Biosciences Announces $55 Million Series A Financing to Advance Precision Medicine Approach for Rare and...

                            Details : The proceeds will advance precision medicine approach for rare and common diseases and its lead small molecule program targeting TRPV4 mutations advancing toward clinic for treatment of Charcot-Marie-Tooth disease type 2C and other serious bone diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 09, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Canaan Partners

                            Deal Size : $55.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth